Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS, June 26, 2025--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents.
With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility.
Julien Torgue, Chief Scientific Officer of Orano Med, stated:
"The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners."
Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S.
This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide.
A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center
Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added:
"This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment."
About Orano Med
Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: http://www.oranomed.com
About Orano
As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow.
Orano, giving nuclear energy its full value.
About Targeted Alpha Therapy
Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250626176840/en/
Contacts
Mike SinclairHalsin Partnersmsinclair@halsin.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
29 minutes ago
- CBS News
"eBay for government" helps agencies and schools auction off property, Municibid founder says
A little slice of land in Ambridge Borough could be yours at a steep discount, and all the proceeds will benefit the local community. "We're like an eBay for government," said Greg Berry, CEO and founder of online government auction site Municibid. Berry says his company helps local governments auction off anything, from parcels of land and old desks to school buses and riding mowers. So far, about 7,000 local governments and schools use the online site to sell unneeded items to the public. The latest listing in Ambridge consists of a nearly 4,000-square-foot parcel of land along Glenwood Drive. Twenty-two bids have already been placed at just over $5,000. "A lot of times, smaller towns, and larger ones, have excess land or land that they've come into own in some form, and they don't have a need for it and they're looking to sell it," said Berry. He said maybe in this case, a neighbor wants to expand or a new park could pop up in the space. Berry says governments sell just about everything on his site. "While it's typically vehicles and heavy equipment and tools and land and things that you might expect the government to have and no longer need, it could be anything, such as sailboats and airplanes and jewelry and electric guitars," Berry said. Municibid allows consumers to sort and shop by state, borough or category. And when a winner scores a deal, here's how the costs break down. "When the auction closes and there's a winning bidder, the winning bidder pays us 9% of the winning bid amount, and then they pay 100% of the bid amount to the selling agency," Berry said. Gone are the days of going to the town hall to fill out a sealed bid. Berry told KDKA he used to work as a borough councilor and found that process far from transparent. "No one knew what the governments were selling, and if they did, the process was super inconvenient and intimidating and just wasn't very easy," said Berry. Besides the Ambridge property, KDKA found a lot of items up for grabs in the Pittsburgh area, including an ATV in Mt. Lebanon, a 2020 Ford Explorer in Castle Shannon, a Ford Crown Victoria police car in New Castle, and golf carts in Greensburg. Berry told KDKA some parents snag their teenagers' first car on the site, or business owners land some needed equipment at a fraction of the price.
Forbes
32 minutes ago
- Forbes
Crisis Averted—But What Was The Section 899 Revenge Tax Proposal?
WASHINGTON, DC - APRIL 23: U.S. Treasury Secretary Scott Bessent delivers remarks during the ... More International Finance Institute Global Outlook Forum at the Willard InterContinental Washington on April 23, 2025 in Washington, DC. The forum is being held alongside the 2025 spring meetings of the World Bank Group (WBG) and International Monetary Fund (IMF). (Photo by) There are myriad ways to express displeasure with international tax policy: you can file a complaint at the Organisation for Economic Co-operation and Development (OECD), leverage a charm offensive, or, if you're looking for a quick fix, you can slap a retaliatory tax on foreign investors, spook the market, and call it a day. The Trump administration opted for the latter—albeit briefly—with the seemingly now-defunct Section 899 provision, branded by some as the 'revenge tax.' This provision, tucked into the One Big Beautiful Bill Act, levied a targeted tax meant to punish countries that impose 'discriminatory' taxes on American firms – particularly tech giants. Now however, after some handshakes and a flurry of posts on social media, it seems the revenge tax has been scrapped. Quietly scuttled, its political usefulness exhausted—for now. What Was the Section 899 'Revenge Tax?' At its core, Section 899 was a legislative jab aimed squarely at America's trading partners. Buried in the GOP's sweeping policy bill, the provision would have authorized the U.S. to impose punitive taxes on companies headquartered in countries that were, in the view of the Trump administration, treating American firms unfairly. The sweeping new section of the tax code would have been titled 'Enforcement of Remedies Against Unfair Foreign Taxes'—not exactly a subtle start. Section 899 didn't go after governments that it felt had treated U.S. firms unfairly, but instead targeted people and businesses with ties to 'discriminatory foreign countries.' That included foreign individuals, corporations not majority-owned by U.S. persons, private foundations and trusts, and just about any other foreign partnership or structure that Treasury didn't like the looks of. The goal was clear: foreign investors from offending jurisdictions were going to be made to feel real economic pain. The core mechanism was an annual ratcheting-up of tax rates by 5% on the U.S. income of 'applicable persons' – everything from dividends and royalties to capital gains and even real estate sales. Exceptions were few – the legislation even explicitly overrode Section 892, which exempts sovereign wealth funds from taxation. The triggering mechanism for the tax was any broadly-defined 'unfair foreign tax,' which included the Undertaxed Profits Rule from OECD's Pillar 2, Digital Services Taxes (DSTs), and any other tax Treasury later deemed discriminatory or deliberately burdensome to U.S. persons. In sum, it would have been sweeping. If passed, Section 899 would have been a weaponization of the tax code into a tool of transparent foreign policy enforcement. It would have marked a sea change in international tax policy, shifting tax rates away from economics and towards the punishment of deemed foreign policy sins. What Prompted this 'Revenge?' Likely the most salient policy shift that triggered this revenge tax was the OECD's Pillar 2. Championed by the Biden administration, Pillar 2 aims to impose a 15% global minimum tax on the profits of multinationals—regardless of where they are headquartered or what markets they serve. On paper, it was intended to end the race to the bottom of low-tax jurisdictions; in practice, it creates a complex web of policies and enforcement rules that can allow foreign governments to tax U.S. companies in situations where the U.S. does not. The Undertaxed Profits Rule allows other countries to claim the ability to tax if a company's home jurisdiction does not sufficiently tax its own domestic entities. Think of it as a foreign state saying, well, if you aren't going to tax your companies at 15%, we'll gladly make up the difference for you. To the Trump administration, this was unacceptable—a path to the European Union skimming revenue from American companies. The final straw was likely the imposition of DSTs—levies aimed at the revenue of tech giants like Meta and Google, often imposed by European countries that have grown tired of waiting for the U.S. to sign on to Pillar 2. Of course, countries considering and ultimately passing DSTs were merely exercising their right to tax American companies selling into their markets—but that is neither here nor there. Why Section 899 Was a Problem—And Why It Died For all its bluster, Section 899 had one main flaw: it was bad policy masquerading as tough politics. From the moment the bill hit the docket, or more accurately folks found it swimming around in the One Big Beautiful Bill Act, alarms went off across the market. As it turns out, foreign investment doesn't like uncertainty. Section 899 would have injected a lot of uncertainty into the foreign investment market. The tax hikes weren't automatic, and there was no schedule that could be consulted by any one individual state; they turned on vague determinations like what was and wasn't an 'unfair tax.' Treasury could label a state a discriminatory foreign country based on opaque criteria and ramp up rates immediately—all without Congress lifting a finger. As is to be expected, trade groups warned of chilling effects on capital markets. Foreign governments viewed it as a backdoor sanctions regime. So it died – not with a bang, but with a post. Scott Bessent publicly called for the provision's removal, citing diplomatic progress. The death of the Revenge Tax doesn't mean this particular international tax skirmish is over, however, only that the battle was paused temporarily in favor of diplomacy. If global talks stall, or DSTs raise their heads again, no one should be surprised if a future Congress pulls out this playbook again.
Fast Company
38 minutes ago
- Fast Company
Nvidia stock price hits fresh record high as analyst sees ‘golden wave' of Gen AI adoption
Shares of Nvidia Corp (Nasdaq: NVDA) reached a new record high on Thursday in premarket trading. As of the time of writing, the stock had peaked at $156.99 before slightly sliding to $156.68. The uptick follows Wednesday's all-time high closing price of $154.31, which rose to $154.59 in after-hours trading. DeepSeek and tariffs worried investors earlier this year Nvidia has been a de facto representative of AI investment in the market. It reached a high of $153.13 in early January, but its shares soon tumbled alongside China's success with AI company DeepSeek and uncertainty around tariffs. DeepSeek used Nvidia chips to build its AI systems despite the United States banning their sale to China. The stock hit a low of $86.62 on April 7, just five days after President Trump's 'Liberation Day,' on which he announced a series of tariffs worldwide. But now, at nearly double that price, it has recovered its losses—and signaled a renewed investment in AI. However, it comes as the dollar hits a three-year low after reports that Trump will move up his selection of a new Federal Reserve chair, the Wall Street Journal reports. What's fueling Nvidia's recent rally? The chipmaker's current ascension was fueled in part by Loop Capital's decision yesterday to raise its price target from $175 to $250. 'Our work suggests we are entering the next 'Golden Wave' of Gen AI adoption, and NVDA is at the front-end of another material leg of stronger than anticipated demand,' Loop Capital analyst Ananda Baruah stated in a client note, according to Reuters. Helped along by Nvidia's 4% rise on Wednesday, the Nasdaq composite also neared its record high with a 0.3% increase.
